Italia markets open in 10 minutes

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
15,83-0,90 (-5,38%)
Alla chiusura: 05:35PM CET

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del VallEs
Barcelona 08174
Spain
34 93 571 00 00
http://www.grifols.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno23.431

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Raimon Grifols RouraCo-CEO & Exec. Director1,17MN/D1964
Mr. Víctor Grífols DeuCo-CEO & Exec. Director1,17MN/D1977
Mr. Alfredo Arroyo GuerraCFO & VPN/DN/D1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/DN/DN/D
Ms. Nuria Pascual LapeñaVP of Corp. Treasury & Investor RelationsN/DN/D1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/DN/D1955
Ms. Maria Teresa-Rioné LlanoVP of Corp. CommunicationsN/DN/D1966
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/DN/D1956
Mr. Francisco Javier Jorba RibesCorp. VP and Pres of the Biological Industrial GroupN/DN/D1951
Mrs. Montserrat Lloveras CalvoCorp. VP and Director of Corp. Accounting & ReportingN/DN/D1962
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Governance aziendale

L'ISS Governance QualityScore di Grifols, S.A. al 26 settembre 2021 è 3. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 9; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.